A Phase I/IIa Clinical Trial to Assess the Safety, Tolerability, and Efficacy of a Single Intravitreal Injection of SPVN20 Gene Therapy in Participants With Advanced Rod-Cone Dystrophy

Study Summary

This open-label, multi-center study is to evaluate the safety, tolerability, and efficacy of escalating doses of a gene therapy called SPVN20 administered via a single intravitreal injection in participants with advanced Rod-Cone Dystrophy.

Interventions

Study Locations

Facility	City	State	Country
Ghent University Hospital	Ghent		Belgium
CHNO XV-XX Paris - CIC 1423	Paris		France
Royal Victoria Eye And Ear Hospital	Dublin		Ireland

Official Trial Information

View on ClinicalTrials.gov